Drug General Information
Drug ID
D0C0SZ
Former ID
DNCL002290
Drug Name
PRT6207
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [551514]
Target and Pathway
Target(s) Tyrosine-protein kinase SYK Target Info Modulator [544430]
KEGG Pathway NF-kappa B signaling pathway
PI3K-Akt signaling pathway
Osteoclast differentiation
Platelet activation
Natural killer cell mediated cytotoxicity
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Fc gamma R-mediated phagocytosis
Tuberculosis
Epstein-Barr virus infection
Viral carcinogenesis
PANTHER Pathway B cell activation
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
BCR signaling pathway
GMCSF-mediated signaling events
Atypical NF-kappaB pathway
Osteopontin-mediated events
FAS (CD95) signaling pathway
Thromboxane A2 receptor signaling
IL2-mediated signaling events
Class I PI3K signaling events
Alpha-synuclein signaling
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome GPVI-mediated activation cascade
FCGR activation
Regulation of actin dynamics for phagocytic cup formation
Role of phospholipids in phagocytosis
DAP12 signaling
Fc epsilon receptor (FCERI) signaling
Role of LAT2/NTAL/LAB on calcium mobilization
FCERI mediated MAPK activation
FCERI mediated Ca+2 mobilization
Integrin alphaIIb beta3 signaling
Interleukin-2 signaling
CLEC7A (Dectin-1) signaling
Dectin-2 family
Regulation of signaling by CBL
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways IL-2 Signaling Pathway
IL-3 Signaling Pathway
Fc epsilon receptor (FCERI) signaling
Signaling by the B Cell Receptor (BCR)
Interleukin-2 signaling
Fcgamma receptor (FCGR) dependent phagocytosis
DAP12 interactions
B Cell Receptor Signaling Pathway
RANKL/RANK Signaling Pathway
Integrin alphaIIb beta3 signaling
GPVI-mediated activation cascade
Regulation of toll-like receptor signaling pathway
IL-5 Signaling Pathway
References
Ref 551514More Than 900 Medicines and Vaccines in Clinical Testing Offer New Hope in the Fight Against Cancer. Pharmaceutical Research and Manufacturers of America report. 2012.
Ref 544430Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.